Format

Send to

Choose Destination
J Clin Invest. 2004 Jan;113(2):169-74.

Cellular senescence in cancer treatment: friend or foe?

Author information

1
Department of Hematology, Oncology, and Tumor Immunology, Humboldt University, Charité, Berlin, Germany.

Abstract

Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of senescence is a beneficial or, rather, a detrimental consequence of the therapeutic intervention.

PMID:
14722606
PMCID:
PMC311442
DOI:
10.1172/JCI20784
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center